Nanobiotix (NANO) Status Update summary

Strategic focus and platform development

• Emphasis on developing first-in-class therapeutics using physics-based platforms, targeting broad patient populations.

• NBTXR3, a radioenhancer for oncology, is prioritized for market launch in partnership with Johnson & Johnson, targeting large untapped markets.

• Curadigm platform introduced, aiming to transform drug delivery and design, with applications across RNA, DNA, oncolytic viruses, and more.

• Business model includes both internal product development and external partnerships or licensing.

Curadigm and Nanoprimer technology overview

• Nanoprimer is a lipid-based nanoparticle administered before therapeutics to transiently occupy liver clearance cells, increasing systemic bioavailability.

• Demonstrated to improve delivery and efficacy of various agents, including RNA therapeutics, small molecules, and recombinant proteins in preclinical models.

• Nanoprimer's effect is transient (about 24 hours), biodegradable, and does not encapsulate active pharmaceutical ingredients.

• Enables rethinking therapeutic design by separating bioavailability from other drug functions, potentially boosting efficacy and reducing toxicity.

Differentiation, safety, and synergy

• Nanoprimer offers synergy with other targeting strategies and does not preclude additional molecular targeting.

• Safety profile is favorable in preclinical studies, with no observed toxicity or immunological activation.

• Does not interfere with cytochrome-mediated metabolism, supporting use in combination regimens.

• Transient action avoids long-term off-target accumulation, differentiating it from pegylated delivery systems.